Cyclin-dependent kinase inhibitors (CDKi) have high potential applicability in anticancer therapy, but various aspects of their pharmacokinetics, especially their interactions with drug efflux transporters, have not yet been evaluated in detail. Thus, we investigated interactions of five CDKi (purvalanol A, olomoucine II, roscovitine, flavopiridol and SNS-032) with the ABCB1 transporter. Four of the compounds inhibited efflux of two ABCB1 substrates, Hoechst 33342 and daunorubicin, in MDCKII-ABCB1 cells: Olomoucine II most strongly, followed by roscovitine, purvalanol A, and flavopiridol. SNS-032 inhibited ABCB1-mediated efflux of Hoechst 33342 but not daunorubicin. In addition, purvalanol A, SNS-032 and flavopiridol lowered the stimulated ATPase activity in ABCB1 membrane preparations, while olomoucine II and roscovitine not only inhibited the stimulated ATPase but also significantly activated the basal ABCB1 ATPase, suggesting that these two CDKi are ABCB1 substrates. We further revealed that the strongest ABCB1 inhibitors (purvalanol A, olomoucine II and roscovitine) synergistically potentiate the antiproliferative effect of daunorubicin, a commonly used anticancer drug and ABCB1 substrate, in MDCKII-ABCB1 cells as well as in human carcinoma HCT-8 and HepG2 cells. We suggest that this pronounced synergism is at least partly caused by (i) CDKi-mediated inhibition of ABCB1 transporter leading to increased intracellular retention of daunorubicin and (ii) native cytotoxic activity of the CDKi. Our results indicate that co-administration of the tested CDKi with anticancer drugs that are ABCB1 substrates may allow significant dose reduction in the treatment of ABCB1-expressing tumors.

Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Prague Hradec Kralove Czech Republic

Zobrazit více v PubMed

Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B (2003) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140–141: 133–143. PubMed

Staud F, Pavek P (2005) Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37: 720–725. PubMed

Staud F, Ceckova M, Micuda S, Pavek P (2010) Expression and Function of P-Glycoprotein in Normal Tissues: Effect on Pharmacokinetics. In: Zhou J, editor. Multi-Drug Resistance in Cancer: Humana Press. pp. 199–222. PubMed

Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13: 379–393. PubMed

Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215–236. PubMed PMC

Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, Hillgren KM (2012) Highlights from the International Transporter Consortium second workshop. Clin Pharmacol Ther 92: 553–556. PubMed

Li Y, Yuan H, Yang K, Xu W, Tang W, et al. (2010) The structure and functions of P-glycoprotein. Curr Med Chem 17: 786–800. PubMed

Staud F, Ceckova M, Micuda S, Pavek P (2010) Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 596: 199–222. PubMed

Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398. PubMed

Shapiro AB, Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250: 130–137. PubMed

Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38: 69–74. PubMed

Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, et al. (2012) HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Res 72: 4204–4213. PubMed PMC

Shukla S, Ohnuma S, Ambudkar SV (2011) Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 12: 621–630. PubMed PMC

Dai Y, Grant S (2003) Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 3: 362–370. PubMed

Krystof V, Uldrijan S (2010) Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 11: 291–302. PubMed

Cicenas J, Valius M (2011) The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 137: 1409–1418. PubMed

Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770–1783. PubMed

Hofman J, Ahmadimoghaddam D, Hahnova L, Pavek P, Ceckova M, et al. (2012) Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol Res 65: 312–319. PubMed

Hofman J, Kucera R, Cihalova D, Klimes J, Ceckova M, et al... (2013) Olomoucine II, but not Purvalanol A, is transported by Breast Cancer Resistance Protein (ABCG2) and P-glycoprotein (ABCB1). PLOS One: In press. PubMed PMC

Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, et al. (2010) Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 46: 3243–3250. PubMed

Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, et al. (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27: 6012–6018. PubMed PMC

Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, et al. (2010) Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 28: 3015–3022. PubMed PMC

Wang LM, Ren DM (2010) Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem 10: 1058–1070. PubMed

Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, et al. (2006) Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol 33: 58–65. PubMed

Lalande ME, Ling V, Miller RG (1981) Hoechst 33342 dye uptake as a probe of membrane permeability changes in mammalian cells. Proc Natl Acad Sci U S A 78: 363–367. PubMed PMC

Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, et al. (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171–4179. PubMed

Spoelstra EC, Westerhoff HV, Dekker H, Lankelma J (1992) Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur J Biochem 207: 567–579. PubMed

Tang F, Ouyang H, Yang JZ, Borchardt RT (2004) Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. J Pharm Sci 93: 1185–1194. PubMed

Wang EJ, Casciano CN, Clement RP, Johnson WW (2000) In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 28: 522–528. PubMed

Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, et al. (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59: 238–245. PubMed

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55. PubMed

Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621–681. PubMed

Guendel I, Agbottah ET, Kehn-Hall K, Kashanchi F (2010) Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther 7: 7. PubMed PMC

Schang LM, St Vincent MR, Lacasse JJ (2006) Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother 17: 293–320. PubMed

Holcakova J, Tomasec P, Bugert JJ, Wang EC, Wilkinson GW, et al. (2010) The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir Chem Chemother 20: 133–142. PubMed PMC

Wang E-j, Casciano CN, Clement RP, Johnson WW (2001) Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun 289: 580–585. PubMed

Rajnai Z, Mehn D, Beery E, Okyar A, Jani M, et al. (2010) ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos 38: 2000–2006. PubMed

Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, et al. (2009) The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos 37: 946–955. PubMed

Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333: 788–796. PubMed

Kamath AV, Chong S, Chang M, Marathe PH (2005) P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother Pharmacol 55: 110–116. PubMed

Chu X, Bleasby K, Evers R (2013) Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol 9: 237–252. PubMed

O'Connor R (2009) A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance. Curr Cancer Drug Targets 9: 273–280. PubMed

Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, et al. (2005) Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33: 1083–1096. PubMed

Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, et al. (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902–5910. PubMed

Coley HM, Shotton CF, Thomas H (2007) Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines. Anticancer Res 27: 273–278. PubMed

Abaza MS, Bahman AM, Al-Attiyah RJ (2008) Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. World J Gastroenterol 14: 5162–5175. PubMed PMC

Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, et al. (2009) Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 124: 465–472. PubMed

Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme

MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption